Publication: Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer
Loading...
Program
KU-Authors
Organization Authors
Co-Authors
Jimenez-Vacas, Juan M.
Westaby, Daniel
Figueiredo, Ines
De Haven Brandon, Alexis
Padilha, Ana
Yuan, Wei
Seed, George
Bogdan, Denisa
Gurel, Bora
Bertan, Claudia
Date
Language
Type
Embargo Status
No
Journal Title
Journal ISSN
Volume Title
Alternative Title
Abstract
Metastatic castration-resistant prostate cancer (mCRPC) is a lethal disease requiring additional therapeutic strategies. MCL1, an anti-apoptotic BCL2 family member, promotes cancer-cell survival, but its role in mCRPC remains poorly understood. Here, we characterise MCL1 in multiple mCRPC biopsy cohorts and patient-derived models, assessing responses to MCL1 inhibition. MCL1 copy number gain (14%-34%) correlates with increased MCL1 expression and worse outcomes. MCL1 inhibition exhibits anti-tumour effects in MCL1-gained mCRPC models. Co-inhibition of MCL1 and AKT induces cancer-specific cell death in PTEN-loss/PI3K-activated models in vitro and in vivo, modulating BAD-BCLXL and BIM-MCL1 interactions, with durable anti-tumour activity in models with AKT inhibitor acquired resistance. Finally, CDK9-mediated MCL1 downregulation combined with AKT inhibition recapitulates these findings, providing further opportunities for clinical translation. These data support early phase clinical trials targeting MCL1, both as monotherapy for MCL1-gained mCRPC, and in combination with AKT inhibition for PTEN-loss/PI3K-activated mCRPC.
Source
Publisher
Nature Portfolio
Subject
Citation
item.page.haspartof
Source
Nature Communications
item.page.ispartofseries
item.page.edition
DOI
10.1038/s41467-025-64042-5
item.page.datauri
item.page.link
Rights
Copyrighted
Copyrights Note
Rights and licensing
Copyrighted
